Publication | Closed Access

Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study

Hematological MalignancyOncologyHematologyPharmacologyChronic Myelomonocytic LeukaemiaPharmacotherapyMedicineMyelodysplastic SyndromesPhase 3Myeloid Neoplasia